GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (ASX:NOX) » Definitions » Research & Development

Noxopharm (ASX:NOX) Research & Development : A$1.45 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Noxopharm Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Noxopharm's Research & Development for the six months ended in Dec. 2023 was A$1.45 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was A$1.45 Mil.

Noxopharm Research & Development Historical Data

The historical data trend for Noxopharm's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm Research & Development Chart

Noxopharm Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Research & Development
Get a 7-Day Free Trial - 7.33 - - -

Noxopharm Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.08 - 5.80 - 1.45

Noxopharm Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$1.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noxopharm  (ASX:NOX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Noxopharm Research & Development Related Terms

Thank you for viewing the detailed overview of Noxopharm's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Noxopharm (ASX:NOX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (ASX:NOX) » Definitions » Research & Development
Comparable Companies
ASX:AGN ASX:BIO ASX:RAD ASX:EZZ ASX:PAA ASX:CYP ASX:ACW ASX:1AI ASX:VBS ASX:KZA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
NOXOF:USA
Address
60 Linksley Ave, Glenhaven, NSW, AUS, 2156
Website
https://www.noxopharm.com
Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.

Noxopharm (ASX:NOX) Headlines

No Headlines